Reporte zur Charge PN7KN

Symptomtext

dose of Tdap on 2020 and Boostrix on 2021; This case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 47-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number PN7KN, expiry date 29th January 2023) for prophylaxis. Co-suspect products included dtpa vaccine. pre-filled syringe device (Boostrix Pre-Filled Syringe Device) injection syringe for prophylaxis. Previously administered products included ADACEL (TDAP) (received on an unknown date in September 2020). On 8th October 2021, the patient received Boostrix and Boostrix Pre-Filled Syringe Device. On 8th October 2021, unknown after receiving Boostrix and Boostrix Pre-Filled Syringe Device, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional details were provided as follows: The reporter was patient's assistance. The patient received a dose of Boostrix one year apart from Tdap Adacel which led to shortening of vaccination schedule. The reporter did consent to follow-up.